SKU:K1319 | M. Wt:336.39 | ||
Formula:C19H20N4O2 | Solubility:No | ||
Purity:>99% | Storage:2 years at -20 degrees centigrade | ||
CAS No.:714272-27-2 | Synonyms:N/A | ||
Chemical NameN/A |
供货周期: | 一周 |
品牌: | |
规格: | 2mg |
货号: | K1319 |
CAS号: | 714272-27-2 |
SKU:K1319 | M. Wt:336.39 | ||
Formula:C19H20N4O2 | Solubility:No | ||
Purity:>99% | Storage:2 years at -20 degrees centigrade | ||
CAS No.:714272-27-2 | Synonyms:N/A | ||
Chemical NameN/A |
Description | NPI-2358 (Plinabulin) | |||||
---|---|---|---|---|---|---|
Targets | ||||||
IC50 | N/A | |||||
In vitro | Plinabulin(NPI-2358), a potent antimicrotubule, is a synthetic analog of NPI-2350. NPI-2358 binds to the colchicine-binding site of tubulin. NPI-2358 has potent in-vitro anti-tumor activity against various human tumor cell lines and maintains activity against tumor cell lines with various multidrug-resistant (MDR) profiles. NPI-2358 dose dependently increases HUVEC monolayer permeability--an in-vitro model of tumor vascular collapse. NPI-2358 in HUVECs was more potent than either colchicine or vincristine. | |||||
In vivo | At the RP2D of 30 mg/m?, plinabulin showed a favorable safety profile, while eliciting biological effects as evidenced by decreases in tumor blood flow, tumor pain, and other mechanistically relevant adverse events Plinabulin (7.5 mg/kg) significantly reduced the initial area under curve (IAUC) and the transfer constant (K(trans)) within 1 hour after injection. No significant anti-tumour effects were observed in the C3H tumours until doses of 12.5 mg/kg were achieved, but started at 1.5 mg/kg in the KHT sarcoma. | |||||
Clinical Trials | N/A | |||||
Features | N/A |
相关产品
重组人肌球蛋白轻链2(Recombinant Human MYL2)
重组大鼠抵抗素(Rat Resistin)
大鼠酸性磷酸酶(ACP)ELISA Kit
大鼠胆囊收缩素/缩胆囊素八肽(CCK-8)ELISA Kit
人瘦素(LEP)ELISA Kit
重组人半乳糖凝集素16/LGALS16 Human
重组人半乳糖凝集素8/Human LGALS8 His
重组人半乳糖凝集素3/Human LGALS3 His
重组人卵泡抑素/Human FST His
重组人β防御素118/DEFB118 Human
重组人心肌营养素1/CTF1 Human
特级新生牛血清(无支原体)
超级新生牛血清(无支原体)
优级胎牛血清(无支原体)
特级新生牛血清(无噬菌体低内毒素)
详细地址
关注
拨打电话
留言咨询